JMV 2959


Catalog No. Size PriceQuantity
M18772-C Contact sales@xcessbio.com for quotation $100Unavailable

Description

JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM.

Product information

CAS Number: 925238-89-7

Molecular Weight: 508.61

Formula: C30H32N6O2

Chemical Name: 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-{4-[(4-methoxyphenyl)methyl]-5-(2-phenylethyl)-4H-1,2,4-triazol-3-yl}ethyl]acetamide

Smiles: COC1C=CC(CN2C(=NN=C2CCC2C=CC=CC=2)[C@@H](CC2=CNC3C=CC=CC2=3)NC(=O)CN)=CC=1

InChiKey: OZSZELOMMMKWTM-HHHXNRCGSA-N

InChi: InChI=1S/C30H32N6O2/c1-38-24-14-11-22(12-15-24)20-36-28(16-13-21-7-3-2-4-8-21)34-35-30(36)27(33-29(37)18-31)17-23-19-32-26-10-6-5-9-25(23)26/h2-12,14-15,19,27,32H,13,16-18,20,31H2,1H3,(H,33,37)/t27-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 250 mg/mL (491.54 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM. JMV 2959 does not induce any intracellular calcium mobilization by itself.

In Vivo:

When administered alone, it does not increase food intake and does not significantly stimulate growth hormone (GH) release. JMV 2959 dose dependently decreases the startle response (F(3.42)=4.4, p<0.01) and increases %prepulse inhibition (PPI) (F(3.42)=3.9, p<0.05) in the prepulse inhibition paradigm. The alteration in the startle response is mainly due to a 27% decrease in the startle seen in the highest dose of JMV 2959 (6 mg/kg) compare to vehicle (p<0.05). 6 mg/kg JMV 2959 induces a significant suppression of locomotion on days 1 to 7 relative to baseline day 0 (F(7,49)=2.21, p<0.05). Results also reveal a significant interaction between JMV 2959 treatment and day (F(1,14)=4.397, p<0.05).

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

You may also like

Recently viewed